Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622604 | 0.96 | ACHE (0.34) | ACHEABCB1 | |
| SCHEMBL4622593 | 0.94 | ACHE (0.33) | ACHEMEN1KMT2AHTTABCB1 | |
| SCHEMBL4233113 | 0.94 | ACHE (0.32) | ACHEABCB1 | |
| SCHEMBL4235778 | 0.93 | ABCB1 (0.35) | ACHEMEN1KMT2AHTTABCB1 | |
| SCHEMBL4240309 | 0.93 | ACHE (0.31) | ACHE | |
| SCHEMBL4233310 | 0.91 | CACNA1H (0.30) | ACHE | |
| SCHEMBL4237858 | 0.87 | MEN1 (0.35) | MEN1KMT2AHTTABCB1KDM4E | |
| SCHEMBL4236151 | 0.87 | P2RY1 (0.32) | ACHEALDH1A1MAPT | |
| SCHEMBL4237713 | 0.86 | ABCB1 (0.33) | ACHEABCB1 | |
| SCHEMBL4238561 | 0.84 | ABCB1 (0.32) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | ACHE 2474/4885MEN1 1007/4885KMT2A 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.